Discovery Program

Clarity’s SAR Technology platform can be used in conjunction with any number of cancer-targeting molecules to create new radiopharmaceutical products, which forms the basis of Clarity’s Discovery Program.

Clarity has a number of R&D projects in its Discovery Program, including:

• New pipeline products; and
• Second generation technology.

In December 2024, Clarity announced the development of a new preclinical stage asset called ^64/67Cu-SAR-bisFAP, a pan-cancer Targeted Copper Theranostic.

• ^64/67Cu-SAR-bisFAP is a proprietary fibroblast activation protein (FAP)-targeted radiopharmaceutical product that can be used with the perfect pairing of copper isotopes for the diagnosis and treatment of cancer.
• The product has shown strong tumour targeting, retention and pharmacokinetic data in pre-clinical models.
• FAP is expressed widely across a range of malignancies, opening a very large pan-cancer opportunity for both imaging and treatment of various cancers.

In February 2025, Clarity announced the development of a new preclinical stage asset called ^64/67Cu-SAR-Trastuzumab.

• Combining the well-established trastuzumab antibody with Clarity’s proprietary SAR Technology enables the development of a copper-67 (Cu-67) based radioimmunotherapy (RIT) for HER2-positive breast cancer patients.
• It is estimated that 316,950 women will be diagnosed with invasive breast cancer in 2025 in the US, with 42,170 dying from the disease¹.
• Human epidermal growth factor receptor 2 (HER2) is expressed in up to 20% of breast cancers and is associated with a more aggressive type of tumour and poor prognosis².
• Pre-clinical evidence shows dose-response reduction in tumour size and prolonged survival using ⁶⁷Cu-SAR-trastuzumab compared to trastuzumab alone in a HER2-positive tumour mouse model³.
• To secure supply of clinical-grade Good Manufacturing Practice (GMP) trastuzumab, Clarity signed a Supply Agreement with EirGenix, Inc. in February 2025.

¹Siegel et al. Cancer statistics, 2025. CA Cancer J Clin. 2025.

²Exman et al. HER2-positive metastatic breast cancer: a comprehensive review. Clin Adv Hematol Oncol. 2021.

³Rudd et al. Potential theranostics of breast cancer with copper-64/67 sarcophagine-trastuzumab. Chem Sci. 2025.

 

Clarity continues to expand its pipeline with a range of Discovery programs ongoing. The majority of the Discovery work is done in collaboration with Clarity’s academic partners and external commercial service providers. The funding of the Discovery research is partially supported by grants and the Australian R&D Tax Incentive.